MCOLN1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8154192	0.50	8/20
SCHEMBL6305458	0.46	8/20
SCHEMBL6305460	0.46	8/20
SCHEMBL6303617	0.47	7/20
SCHEMBL6303621	0.47	7/20
SCHEMBL6311405	0.59	6/20
SCHEMBL6311411	0.59	6/20
SCHEMBL6307561	0.55	6/20
SCHEMBL6307563	0.55	6/20
SCHEMBL11603608	0.55	6/20
SCHEMBL11603611	0.55	6/20
SCHEMBL11603615	0.55	6/20
SCHEMBL6306235	0.51	6/20
SCHEMBL6306239	0.51	6/20
SCHEMBL11385108	0.50	6/20
SCHEMBL6303757	0.49	6/20
SCHEMBL6303763	0.49	6/20
SCHEMBL6310941	0.49	6/20
SCHEMBL6310948	0.49	6/20
Hydrochloric Acid (SCHEMBL9250992)	0.49	6/20

Clinical trials — most relevant to MCOLN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3	PHASE3	NOT_YET_RECRUITING
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)	PHASE1	COMPLETED
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype	EARLY_PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Mucolipidosis Type IV Natural History Study	nan	ACTIVE_NOT_RECRUITING
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants	nan	RECRUITING
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Natural History Study of Mitochondrial Myopathy	nan	RECRUITING
Genetic Study of Patients With Primary Ciliary Dyskinesia	nan	COMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)	nan	COMPLETED
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	nan	COMPLETED
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease	nan	ENROLLING_BY_INVITATION
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling	nan	ACTIVE_NOT_RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae	nan	ACTIVE_NOT_RECRUITING
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MCOLN1 binder may also engage these)

Protein	Name	Similarity
Q60HE8	—	1.000	Q60HE8 →
Q99J21	—	0.995	Q99J21 →
Q8R4F0	—	0.971	Q8R4F0 →
Q9P0L9	—	0.970	Q9P0L9 →
A2A259	—	0.967	A2A259 →
PKD2	Polycystin-2	0.963	landscape →
Q7Z403	—	0.963	Q7Z403 →
A6QM06	—	0.962	A6QM06 →
MCOLN3	Mucolipin-3	0.961	landscape →
A2RRU4	—	0.961	A2RRU4 →
A6NDV4	—	0.961	A6NDV4 →
P97260	—	0.960	P97260 →
B1AWJ5	—	0.960	B1AWJ5 →
Q9R283	—	0.960	Q9R283 →
O35245	—	0.959	O35245 →
Q5MNU5	—	0.958	Q5MNU5 →
A1A5B4	—	0.958	A1A5B4 →
Q6GQT6	—	0.958	Q6GQT6 →
TRPM5	Transient receptor potential cation channel subfamily M member 5	0.957	landscape →
Q12770	—	0.957	Q12770 →
Q9JJH7	—	0.957	Q9JJH7 →
F6RG56	—	0.957	F6RG56 →
Q5FVJ6	—	0.956	Q5FVJ6 →
SPPL2B	Signal peptide peptidase-like 2B	0.956	landscape →
P56726	—	0.956	P56726 →
SMO	Protein smoothened	0.956	landscape →
Q4GZT3	—	0.955	Q4GZT3 →
P97698	—	0.954	P97698 →
Q7RTT9	—	0.954	Q7RTT9 →
A6NFA1	—	0.954	A6NFA1 →